Brelovitug AZURE-4 Phase 3 hepatitis D results infographic

Brelovitug, Mirum Pharmaceuticals’ antibody for chronic hepatitis delta, has now succeeded in a second Phase 3 trial: in AZURE-4, announced November 10, 2026, 59% of patients on the weekly 300 mg dose achieved both a major drop in hepatitis D virus and normal liver enzymes at Week 24, against 0% of patients whose treatment was delayed. With two positive pivotal studies in hand, Mirum plans to file for FDA approval in the first half of 2027.

Key takeaways on brelovitug

  • AZURE-4 (n=113) met its primary endpoint: 59% combined response with 300 mg weekly and 44% with 900 mg every four weeks, versus 0% delayed treatment.
  • It is the second pivotal win after AZURE-1 (56% and 45%), giving Mirum the two studies it needs for a US filing.
  • About 95% of treated patients had a virologic response, defined as at least a 100-fold (2 log) fall in HDV RNA or undetectable virus.
  • More than half of AZURE-4 patients (53%) had cirrhosis.
  • No new safety signals; flu-like illness in about 17-19% of patients, mostly after the first dose.
  • BLA filing planned for H1 2027; potential US launch Q4 2027.

AZURE-4 trial design

AZURE-4 was a global, open-label study of 113 treatment-naive adults with chronic hepatitis delta, randomized 2:1:1 to self-injected brelovitug 300 mg once weekly, 900 mg every four weeks, or a delayed-treatment control that started at Week 12. Patients took, or were willing to start, standard hepatitis B nucleos(t)ide therapy. The population was sick: 53% had cirrhosis, about half had very high viral loads (above 6 log10 IU/mL) and mean ALT was 122 U/L, roughly three times the upper limit of normal.

Results side by side

Week 24 endpointAZURE-4 300 mg weeklyAZURE-4 900 mg Q4WAZURE-1 300 mg weeklyAZURE-1 900 mg Q4WDelayed (both trials)
Combined response (primary)59%44%56%45%0%
Virologic response95%96%86%85%0%
ALT normalization60%44%63%54%0%
HDV RNA below LLOQ31%22%25%26%0%
HDV RNA undetectable14%11%17%17%0%
Sources: Mirum AZURE-1 release (Sept 28, 2026) and AZURE-4 topline (Nov 10, 2026). Separate trials, not a head-to-head comparison.

The consistency across two independent trials is the headline. The weekly dose produced 56-59% combined response in both, and the monthly dose 44-45%. Longer treatment appears to help: in AZURE-1’s Phase 2b cohort, combined response reached 55% on both doses by Week 48, and undetectable or near-undetectable virus rose sharply, according to Mirum’s AZURE-1 disclosure.

How brelovitug works

Hepatitis D is a defective virus: it can only infect people who already have hepatitis B, because it borrows the hepatitis B surface antigen (HBsAg) as its outer coat. Brelovitug is a fully human IgG1 monoclonal antibody that binds HBsAg, neutralising infectious particles and clearing the HBsAg-rich subviral particles that circulate in huge numbers. It holds FDA Breakthrough Therapy and Orphan Drug designations and EMA PRIME and Orphan status.

Safety and caveats

No new safety signals emerged in AZURE-4. Flu-like illness occurred in 17.2% (weekly) and 18.5% (monthly) of patients, mostly after the first dose, and injection-site reactions in 1.7% and 7.4%. In AZURE-1, there were no grade 3 or higher adverse events or discontinuations in the active arms through Week 24.

  • Both trials were open-label, which can influence subjective outcomes, though the virus and ALT endpoints are lab measures.
  • The control arms switched to active treatment early (Week 12 or 24), so long-term controlled comparisons are not available.
  • Improvements in liver stiffness have been reported, but do not on their own prove fibrosis regression.
  • Clinical outcomes such as liver failure, cancer and death need longer follow-up.

Where it fits in a crowded new field

Hepatitis D is the most severe form of viral hepatitis. Mirum cites about 230,000 people affected in the US and Europe and estimates that more than half die of liver-related causes within 10 years of diagnosis. Most countries have no approved treatment. Brelovitug is one of several late-stage contenders; Vir’s monthly elebsiran plus tobevibart combination also reported positive Phase 3 data this month (see our ECLIPSE 1 coverage). Endpoints and populations differ, so cross-trial comparisons should be made with care. For context on the parent infection, read our report on hepatitis B treatment advances.

For India, where hepatitis B is common and HDV co-infection is under-diagnosed, the main near-term implication is diagnostic: patients with hepatitis B who have unexplained liver damage should ask about HDV testing, since effective therapies are now approaching approval in major markets. Mirum has not announced plans for India.

FAQ

Is brelovitug FDA approved?

Not yet. Mirum plans to submit a Biologics License Application in the first half of 2027, with a potential US launch in the fourth quarter of 2027 if approved.

How is brelovitug given?

As a subcutaneous injection, studied either weekly or every four weeks. In AZURE-4 the weekly dose was self-administered.

Can hepatitis D be cured?

Current trials aim for durable viral suppression and normal liver enzymes rather than cure. Some patients reached undetectable virus, but long-term off-treatment results are not yet known.

Who can get hepatitis D?

Only people infected with hepatitis B. Hepatitis B vaccination therefore also protects against hepatitis D.

More: Clinical trials news

Sources: Mirum Pharmaceuticals AZURE-4 topline (November 10, 2026) and AZURE-1 Phase 3 release (September 28, 2026); Reuters. No relevant Acumen Research and Consulting report was available for this therapy area. Not medical or investment advice. Last updated: November 12, 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

Leave a Reply

Your email address will not be published. Required fields are marked *